A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of futibatinib with paclitaxel and ramucirumab for the treatment of patients with gastric, gastroesophageal junction or esophageal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving futibatinib with paclitaxel and ramucirumab may be safe and tolerable in treating patients with locally advanced or unresectable gastric, gastroesophageal junction or esophageal adenocarcinoma.

Start Date09 Sep 2027

Sponsor / Collaborator

Northwestern University

[+1]

NCT07763171

/ Not yet recruitingPhase 3IIT

Paclitaxel Plus Ramucirumab and Tislelizumab as Switch Maintenance Versus Continuation of Chemotherapy and Tislelizumab in Patients With Advanced HER2-negative and PD-L1 Positive Gastroesophageal Adenocarcinoma: the ARMANI-2/ENGIC08 Trial by GONO

ARMANI-2/ENGIC8 is a randomized, open-label, phase III trial evaluating a switch maintenance strategy in patients with previously untreated, locally advanced unresectable or metastatic, HER2-negative and PD-L1-positive gastroesophageal adenocarcinoma.
The combination of platinum- and fluoropyrimidine-based chemotherapy with an anti-PD-1 agent represents a first-line treatment option for patients with advanced HER2-negative, PD-L1-positive gastroesophageal adenocarcinoma. However, disease progression remains frequent and may lead to clinical deterioration, preventing a substantial proportion of patients from receiving subsequent anticancer treatment.
The phase III ARMANI trial demonstrated that, in patients with advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma who achieved disease control after 3 months of first-line oxaliplatin- and fluoropyrimidine-based chemotherapy, switching to paclitaxel plus ramucirumab significantly improved progression-free survival and overall survival compared with continuation of the initial chemotherapy. These findings support the early introduction of a non-cross-resistant treatment before the development of chemotherapy-resistant disease and clinical deterioration.
ARMANI-2 builds on this strategy in the current immunotherapy-based treatment setting. In addition, VEGF/VEGFR blockade may have immunomodulatory effects that provide a biological rationale for combining ramucirumab with PD-1 blockade.
All eligible patients will receive a 12-week induction treatment with tislelizumab combined with platinum- and fluoropyrimidine-based chemotherapy (mFOLFOX6, CAPOX, or cisplatin plus fluorouracil). Patients who complete induction without disease progression or permanent treatment discontinuation will be randomized 1:1 to receive either switch maintenance with paclitaxel, ramucirumab, and tislelizumab (Arm A) or continuation of the chemotherapy regimen used during induction in combination with tislelizumab (Arm B).
The primary objective is to determine whether switch maintenance with paclitaxel, ramucirumab, and tislelizumab improves progression-free survival compared with continuation of chemotherapy and tislelizumab. Secondary objectives include overall survival, PFS2, tumor response and disease control, safety, health-related quality of life, and attrition to subsequent anticancer therapy. Exploratory analyses will investigate clinical and translational biomarkers potentially associated with treatment efficacy and early disease progression.

Start Date01 Sep 2026

Sponsor / Collaborator

Gruppo Oncologico del Nord-Ovest

NCT07546812

/ RecruitingPhase 2

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human epidermal growth factor receptor 2 (HER2)-Negative, unresectable, recurrent, and/or metastatic, gastroesophageal junction (GEJ), and esophageal adenocarcinomas.
The primary objective of this study is to assess the effect of DEN as a monotherapy or in combination with nivolumab (NIVO) or ramucirumab (RAM) and paclitaxel (PAC) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version1.1).

Start Date07 Aug 2026

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with Ramucirumab

100 Translational Medicine associated with Ramucirumab

100 Patents (Medical) associated with Ramucirumab

1,249

Literatures (Medical) associated with Ramucirumab

01 Dec 2026·ESMO Gastrointestinal Oncology

Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDA

Article

Author: Esaki, T ; Hirano, H ; Oki, E ; Furuta, M ; Murotani, K ; Narita, Y ; Muro, K ; Ando, K ; Kawakami, H ; Inagaki, C

Background:

Zolbetuximab, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, combined with fluoropyrimidine- and platinum-based chemotherapy, is established as first-line standard of care for patients with CLDN18.2-positive, human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction (GEJ) cancer, based on the phase III SPOTLIGHT and GLOW trials. However, evidence regarding the efficacy and safety of continuing zolbetuximab beyond disease progression remains lacking. Given reports that CLDN18.2 expression is maintained after chemotherapy and the absence of clearly established resistance pathways, continued CLDN18.2-targeted therapy in the second-line setting warrants investigation.

Aim:

To investigate whether the addition of zolbetuximab to second-line nab-paclitaxel plus ramucirumab improves overall survival (OS) in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinoma who have progressed with first-line zolbetuximab-based therapy.

Trial design:

ZELDA (jRCTs071250038) is a multicenter, open-label, randomized phase II (rP2) trial conducted by the West Japan Oncology Group and Kyushu Study Group of Clinical Cancer in Japan. A safety lead-in part (n = 6) confirms the tolerability of the triplet combination (zolbetuximab + nab-paclitaxel + ramucirumab), followed by a rP2 trial (n = 210) with a 1 : 1 allocation to nab-paclitaxel + ramucirumab (arm A, control) or zolbetuximab + nab-paclitaxel + ramucirumab (arm B, experimental). The primary endpoint is OS in the full analysis set. Integrated translational research (ZELDA-TR) is also planned.

01 Nov 2026·JOURNAL OF PHARMACEUTICAL SCIENCES

Comment on “Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI”

Letter

Author: Gite, Kuldip V ; Akotkar, Akshay ; Bhise, Manish R ; Bhandari, Shweta

01 Oct 2026·INTERNATIONAL JOURNAL OF CANCER

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

Article

Author: Sonja Loges ; Stefan Probst ; Sylvie Lorenzen ; Melanie Janning ; Victoria Gensch ; Peter Reichardt ; Peter Thuss-Patience ; Christian Müller ; Claudia Pauligk ; Jurek Hille ; Florian Lordick ; Thorsten O. Goetze ; Martin Sökler ; Carsten Bokemeyer ; Eray Goekkurt ; Salah E. Al-Batran ; Daniel Pink ; Thomas Ettrich

ABSTRACT:

Antiangiogenic treatment with ramucirumab (RAM) is a standard second‐line option in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. However, reliable biomarkers are lacking. The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5‐fluororuracil, leucovorin and irinotecan) in this setting. We present the exploratory biomarker analysis evaluating placental growth factor (PlGF), carbonic anhydrase IX (CAIX), and tryptase. Plasma samples from 99 patients enrolled in RAMIRIS were collected at predefined timepoints (baseline, Cycle 2 Day 1, and Cycle 4 Day 1). PlGF, CAIX, and tryptase were quantified by ELISA. Associations with progression‐free survival (PFS) and overall survival (OS) were analyzed using dichotomized biomarker levels and Cox regression models. PlGF levels increased substantially under treatment, whereas CAIX showed a transient rise, followed by a slight decline, and tryptase remained stable. Elevated PlGF levels at baseline and early‐treatment (c2d1) were associated with shorter OS in univariate analysis (baseline HR u = 1.75; p = 0.020; c2d1 HR u = 1.69; p = 0.054). After multivariate adjustment, the association remained directionally consistent; although statistical support was retained only for c2d1 (baseline HR m = 1.41, p = 0.198; c2d1 HR m = 1.85, p = 0.030). CAIX and tryptase showed no consistent associations with survival. Elevated PlGF—particularly its early increase during RAM‐based therapy—was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis‐generating and require validation in independent biomarker‐driven studies.

288

News (Medical) associated with Ramucirumab

22 Oct 2026

·www.biospace.com

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of patients in breast and lung cancer Additional analyses from two trials of raludotatug deruxtecan in ovarian cancer demonstrate emerging potential in gynecological cancers TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 30 abstracts, including four late breaking presentations, in multiple cancers at the 2026 European Society for Medical Oncology (#ESMO26) Congress. New data from six landmark trials demonstrate the company’s progress toward advancing new standards of care for patients in breast and lung cancer, including the DESTINY-Breast05 ( 539RO ), DESTINY-Breast06 ( 4279P ), DESTINY-Breast09 ( LBA49 ), DESTINY-Breast11 ( 543RO ) and DESTINY-Lung04 ( LBA74 ) phase 3 trials of Enhertu ® (trastuzumab deruxtecan) and the TROPION-Breast02 ( LBA96 ) phase 3 trial of Datroway ® (datopotamab deruxtecan). Additional data at ESMO also will spotlight the company’s commitment to advancing research for patients with advanced ovarian cancer across lines of therapy. An updated analysis, including progression-free survival and duration of response, will be presented from the REJOICE-Ovarian01 ( 1331P ) phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. A mini oral presentation will highlight preliminary findings from the REJOICE-Ovarian02 ( 1247RO ) phase 1b/2 trial evaluating raludotatug deruxtecan in combination with bevacizumab in patients with platinum-resistant ovarian cancer. “The promising data for raludotatug deruxtecan in ovarian cancer and the robust scientific innovation demonstrated across our pipeline reflects our progress in advancing research for patients across multiple types of cancer,” said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. “Daiichi Sankyo continues to draw from its scientific and technological expertise to turn science into new medicines that can change the standard of care.” Data Demonstrate Benefit of DXd ADCs in Patients with Brain Metastases Research updates highlighting the impact of DXd ADCs in patients with brain metastases include late-breaking rapid oral and proffered paper presentations from the DESTINY-Breast09 ( LBA49 ) phase 3 trial evaluating Enhertu in combination with pertuzumab as a first-line treatment for patients with HER2 positive metastatic breast cancer and the TROPION-Breast02 ( LBA96 ) phase 3 trial evaluating Datroway as a first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option. Final overall survival results of the TUXEDO-3 ( 690O ) phase 2 trial of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases from metastatic breast cancer, advanced non-small cell lung cancer (NSCLC) or leptomeningeal disease from any solid tumor will be presented as a proffered paper. New Data and Trials-in-Progress Presentations Across DXd ADC Portfolio Additional data highlighting new research across the DXd ADC portfolio include oral and poster presentations, including final results of the TALENT ( LBA23 ) phase 2 trial of Enhertu alone or in combination with anastrozole, or in sequence with chemotherapy, as neoadjuvant treatment for patients with HR positive, HER2 low early stage breast cancer. New data in NSCLC include the NeoCOAST-2 ( 4244RO ) phase 2 trial reporting event-free survival results, as well as findings on the association of ctDNA clearance with clinical outcomes in patients with resectable, early stage NSCLC treated with a combination of Datroway plus durvalumab and chemotherapy, and a retrospective analysis evaluating mechanisms of insensitivity to the Datroway payload in subgroups of patients with advanced NSCLC in the TROPION-Lung01 ( 4451P ) phase 3 trial. Updated findings from the EPOC2003 ( 2888P ) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer: results from ESPERANZA ( 1014P ), an external comparator study evaluating Enhertu versus real-world standard of care as a second line or later treatment for patients with HER2 IHC 3+ solid tumors; and, the primary analysis evaluating patritumab deruxtecan monotherapy in patients with melanoma in the HERTHENA-PanTumor01 ( 2073RO ) phase 2 trial also will be presented. Trials-in-progress poster presentations include the DESTINY-Breast Guide ( 1795TiP ) prospective and interventional trial evaluating first-line treatment with Enhertu plus pertuzumab followed by palbociclib, endocrine therapy and dual HER2 blockade (trastuzumab plus pertuzumab), as well as retreatment with Enhertu following progression on maintenance therapy (palbociclib, endocrine therapy and trastuzumab plus pertuzumab) in previously untreated patients with HER2 positive advanced or metastatic breast cancer and the TROY ( 1335TiP ) phase 2 trial evaluating Enhertu in patients with recurrent ovarian cancer with disease progression on prior PARP inhibitor therapy. An overview of late-breaking, clinical data and trials-in-progress presentations from the ADC portfolio of Daiichi Sankyo includes: Presentation Title Author Abstract Presentation (CEST) LBAs Final results of TALENT: a neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer S. Hurvitz LBA23 Proffered Paper Presentation Friday, October 23 1:30 pm – 3:00 pm First-line datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: exploratory analysis of patients with brain metastases in TROPION-Breast02 R. Dent LBA96 Proffered Paper Presentation Saturday, October 24 8:30 am – 10:00 am First-line trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant NSCLC: patient-reported outcomes from DESTINY-Lung04 S. Novello LBA74 Rapid Oral Presentation Saturday, October 24 8:30 am – 10:00 am DESTINY-Breast09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab for patients with HER2+ advanced/metastatic breast cancer and baseline brain metastases C. Saura LBA49 Rapid Oral Presentation Monday, October 26 10:15 am – 11:45 am Breast DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab vs. dose-dense doxorubicin + cyclophosphamide followed by THP in HER2+ early breast cancer J.F. Boileau 543RO Rapid Oral Presentation Friday, October 23 4:15 pm – 5:45 pm Patient-reported outcomes from DESTINY-Breast05: health-related quality of life with trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2 positive early breast cancer C. Barrios 539RO Rapid Oral Presentation Friday, October 23 4:15 pm – 5:45 pm Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody-drug conjugate resistance in metastatic breast cancer P. Tarantino 4449RO Rapid Oral Presentation Monday, October 26 10:15 am – 11:45 am Trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy in HR+, HER2 low metastatic breast cancer: a DESTINY-Breast06 ctDNA molecular response analysis G. Curigliano 4279P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm Trastuzumab deruxtecan (T-DXd) + pembrolizumab in previously treated human epidermal growth factor receptor 2-expressing advanced or metastatic breast cancer: primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106 H. Rugo 1771P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm DESTINY-Breast Respond HER2 low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2 low metastatic breast cancer: update on baseline characteristics and anti-emetic treatment J.Y. Pierga 12P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Improving accuracy in HER2 ultralow identification: multi-site validation of an AI-decision support tool B. Van der Vegt 1784P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Comparative evaluation of 7 artificial intelligence tools for HER2-low and ultralow scoring in breast cancer J.S. Frenel 287P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)-based therapy followed by palbociclib, endocrine therapy, and dual HER2 blockade in first-line human epidermal growth factor receptor positive, hormone receptor-positive advanced or metastatic breast cancer and retreatment with T-DXd (DESTINY-Breast Guide) S. Sammons 1795TiP Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Lung NeoCOAST-2: association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial T. Cascone 4244RO Rapid Oral Presentation Sunday, October 25 8:30 am – 10:00 am Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer in TROPION Lung01 N. Girard 4451P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: IDeate-Lung01 updated results M. Ahn 3842P Poster Presentation Monday, October 26 12:00 pm – 12:45 pm Ovarian Raludotatug deruxtecan (R-DXd) + bevacizumab in participants with platinum-resistant recurrent ovarian cancer: results for cohort B-1 of the phase 1b/2 REJOICE-Ovarian02 study A. Oaknin 1247RO Rapid Oral Presentation Saturday, October 24 08:30 am – 10:00 am Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: an updated analysis of efficacy and tolerability from the phase 2 part of REJOICE-Ovarian01 K. Hasegawa 1331P Poster Presentation Monday, October 26 12:00 pm – 12:45 pm A randomized phase 2, open-label, multicenter, study of trastuzumab deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14) J.Y. Lee 1335TiP Poster Presentation Monday, October 26 12:00 pm – 12:45 pm Gastric Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma from DESTINY-Gastric04 M. Gumus 2925P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm Perioperative trastuzumab deruxtecan plus capecitabine and durvalumab in HER2 positive gastric or gastroesophageal junction cancer: a phase II study (EPOC2003) D. Takahari 2888P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm PanTumor Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases and leptomeningeal disease M. Preusser 690O Proffered Paper Presentation Sunday, October 25 10:15 am – 11:45 am Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: primary analysis from HERTHENA-PanTumor01 M. McKean 2073RO Rapid Oral Presentation Sunday, October 25 10:15 am – 11:45 am ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors F. Meric-Bernstam 1014P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of nine ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo. The DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo. Additional ADCs being developed by Daiichi Sankyo include DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING, and DS1025, which consists of a CD25 directed antibody attached to an immuno-oncology optimized cytotoxic payload. Ifinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610, DS3790 and DS1025 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit . Contacts MEDIA CONTACTS: Global: Jennifer Brennan Jennifer.brennan@daiichisankyo.com +1 908 900 3183 (mobile) Japan: DS-PR_jp@daiichisankyo.com INVESTOR RELATIONS CONTACT: DaiichiSankyoIR_jp@daiichisankyo.com

Phase 2Phase 3Clinical ResultADCImmunotherapy

29 Sep 2026

·www.prnewswire.com

2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentation at the 23rd International Myeloma Society (IMS) Annual Meeting 2026. Based on the results of the Phase 1 dose optimization study, the recommended Phase 2 dose (RP2D) of IBI3003 was determined to be 360 μg/kg. At the RP2D, IBI3003 demonstrated rapid, deep, and durable response signals, particularly in heavily pretreated, high-risk patients with extramedullary disease. IBI3003 is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. Its dual-targeting design against BCMA and GPRC5D is intended to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies targeting GPRC5D/CD3 or BCMA/CD3, with particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI3003 in China, Australia, and the United States (NCT06083207 and NCT07336472) to evaluate its safety, tolerability, and preliminary efficacy in patients with R/R MM. In parallel, Innovent has advanced the Phase 3 TriadicMM-1 study (NCT07623798) in China for IBI3003 in patients with R/R MM who have received 1 to 4 prior lines of therapy. ‌ In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861). The updated data were from the Phase 1 clinical study NCT06083207, which enrolled eligible patients with R/R MM who had failed at least two prior lines of therapy, including at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38-based therapy, and who had relapsed or were refractory to their last anti-myeloma regimen. Patients with prior BCMA- and/or GPRC5D-targeted therapy were also eligible for enrollment. IBI3003 was administered subcutaneously once weekly (QW). Patients who received continuous treatment for ≥6 months and achieved a partial response (PR) or better for ≥2 months could switch to once-every-two-weeks (Q2W) dosing for maintenance. To reduce the risk of cytokine release syndrome (CRS), 1 to 3 priming doses were incorporated into the study design. A total of 102 patients were enrolled in this phase of the study in China and Australia, with doses ranging from 0.1 μg/kg to 800 μg/kg. The median patient age was 62 years (range: 40-88), 37.1% of patients were classified as high risk according to mSMART criteria, and 53.9% had ≥1 site of extramedullary disease (EMD). The median number of prior lines of therapy was 4 (range: 2-12). All patients had received at least three classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody. Among them, 55.9% had received at least five classes of therapy, including at least two PIs, two IMiDs, and one anti-CD38 antibody; 33.3% had previously received anti-BCMA and/or anti-GPRC5D therapies; and 88.2% were refractory to their last treatment. As of the data cutoff date of June 30, 2026, the median follow-up duration was 6.65 months (range: 0.8-15.2). Rapid, Deep, and Durable Responses Observed with IBI3003 at 360 μg/kg Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 μg/kg in the Phase 1 study, the RP2D was determined to be 360 μg/kg. A total of 26 patients received IBI3003 at 360 μg/kg, with a median follow-up duration of 7.57 months. mPFS was not reached yet. The overall response rate (ORR) was 84.6%, including 11 cases of stringent complete response (sCR), 4 cases of very good partial response (VGPR), and 7 cases of partial response (PR). The ORR was 94.7% among 19 patients who had received 2 to 4 prior lines of therapy, 87.5% among 8 patients with non-bone-related EMD, and 92.3% among 13 patients without EMD. The median time to first response was 0.99 months (range: 0.9-8.3 months), the median time to first response of ≥VGPR was 1.87 months (range: 0.9-4.6 months), and the median time to first response of ≥CR was 2.79 months (range: 0.9-9.2 months). Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=8). Three patients achieved MRD negativity after receiving only one treatment cycle. Manageable Safety Profile of IBI3003 in Patients with R/R MM Hematologic toxicities were the most common Grade ≥3 treatment-related adverse events (TRAEs), occurring primarily during the dose-escalation phase and being manageable and reversible. The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 52% and 3.9%, respectively. All events were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce the risk of CRS. The incidence of infections was 42.2%, with Grade ≥3 infections reported in 26.5% of patients. For GPRC5D target-related TEAEs involving the oral cavity, skin, and nails, no Grade ≥3 oral TEAEs were observed. Most skin and nail TEAEs were Grade 1-2, with only two patients experiencing Grade 3 rash. Potent and Sustained Pharmacodynamic Responses Observed with IBI3003 in Patients with R/R MM Biomarker analyses showed a significant and sustained decline in serum soluble BCMA (sBCMA) levels across the IBI3003 120 μg/kg, 360 μg/kg, and 540 μg/kg dose groups. Deep and durable reductions in sBCMA levels were observed across all dose groups. After three treatment cycles, the median reduction from baseline in sBCMA levels was 98.38% in the IBI3003 360 μg/kg group. IBI3003 continued to demonstrate encouraging and durable responses, together with a manageable safety profile, in heavily pretreated patients with R/R MM. These efficacy and safety data support further evaluation of the clinical value of IBI3003 in the ongoing Phase 3 clinical study. Professor Peng Liu of Zhongshan Hospital Affiliated to Fudan University stated, "Patients with R/R MM have a poor prognosis after failing treatments including PIs, IMiDs, and anti-CD38-based therapies, with an ORR of only 29.8%, a median progression-free survival of 4.6 months, and a median overall survival of 12.4 months[1]. Although bispecific antibodies are reshaping the treatment landscape of R/R MM, trispecific antibodies targeting two antigens simultaneously may help overcome treatment resistance caused by intra-tumor and inter-tumor heterogeneity, as well as treatment-induced antigen escape. A substantial unmet clinical need remains in R/R MM, particularly among heavily pretreated and high-risk patients. The dual-target coverage of BCMA and GPRC5D by IBI3003 addresses antigen expression heterogeneity and treatment resistance associated with single-target therapies, thereby reducing tumor escape. Its optimized CD3 affinity enables precise T-cell activation and tumor killing while improving safety. In the Phase 1 results presented at this meeting, IBI3003 demonstrated a manageable safety profile and impressive efficacy at the 360 μg/kg dose, with an ORR of 84.6%. Significant efficacy was also observed in patients with EMD or other high-risk features, fully demonstrating the potential of IBI3003 to overcome treatment resistance. The ORR reached 94.7% among patients who had received 2 to 4 prior lines of therapy. We look forward to the results of the ongoing Phase 3 clinical study of IBI3003." About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody) IBI3003 was developed using Innovent's proprietary Sanbody® platform. It is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. The molecule was designed to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies. It also demonstrated particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D. Phase 1/2 clinical trials of IBI3003 (NCT06083207 and NCT07336472) are being conducted concurrently in China, Australia, and the United States to evaluate its safety, tolerability, and efficacy in patients with R/R MM. In China, IBI3003 has advanced into a pivotal registrational clinical stage. TriadicMM-1 (NCT07623798) is a multicenter, randomized, open-label Phase 3 study designed to compare the efficacy and safety of IBI3003 with investigator's choice of therapy in patients with R/R MM who have received 1 to 4 prior lines of therapy. The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC). In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage. Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza®) and selpercatinib (Retsevmo®), pirtobrutinib (Jaypirca®) and abemaciclib (Verzenios®) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage. Forward-Looking Statements of Innovent Biologics This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. SOURCE Innovent Biologics 21% more press release views with Request a Demo

Clinical ResultPhase 1Phase 2Phase 3ASCO

28 Sep 2026

·www.prnewswire.com

Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that the China National Medical Products Administration (NMPA) has approved Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, as a monotherapy for the treatment of adult patient with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This NMPA action expands the Jaypirca® indication to include patients with CLL/SLL across all lines of therapy and regardless of prior covalent BTK inhibitor treatment. Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to target the BTK pathway in patients with CLL/SLL. It has been evaluated across multiple clinical studies in patients with CLL/SLL who were either previously treated with a covalent BTK inhibitor or who were BTK inhibitor-naïve, generating clinical evidence supporting its use across different CLL/SLL treatment settings. The approval is supported by data from the global Phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials. BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with treatment-naïve CLL/SLL. In BRUIN CLL-313, the study demonstrated a statistically significant benefit in independent review committee (IRC)-assessed progression-free survival (PFS) for pirtobrutinib compared with bendamustine plus rituximab (BR) (HR=0.199), representing an 80.1% reduction in the risk of disease progression or death[1]. BRUIN CLL-314 is the first head-to-head Phase 3 CLL/SLL trial to compare covalent and non-covalent BTK inhibitors in a BTK inhibitor-naïve population, which included relapsed and refractory and treatment-naïve patients. In BRUIN CLL-314, the study met its primary endpoint of noninferiority for overall response rate (ORR) in both the intent-to-treat (ITT) population and previously treated patients. Pirtobrutinib achieved a numerically higher ORR compared to ibrutinib. Although PFS data remain immature, a trend toward PFS benefit was observed[2]. Together, these two studies support the clinical value of pirtobrutinib across the CLL/SLL treatment continuum. Prof. Jianyong Li, Principal Investigator of the BRUIN CLL-313 Study in China, said, "BTK inhibitors have significantly transformed the treatment landscape for patients with CLL/SLL in recent years. However, as disease management continues to evolve, there remains a growing need for treatment options that combine durable efficacy with a favorable tolerability profile. As a non-covalent BTK inhibitor, pirtobrutinib has demonstrated meaningful clinical benefit in both treatment-naïve and previously treated patients with CLL/SLL. This approval has the potential to provide a new option for Chinese patients with CLL/SLL across all lines of therapy, meaningfully advancing the management of CLL/SLL throughout the treatment journey." Prof. Luqiu Qiu, Principal Investigator of the BRUIN CLL-314 Study in China, commented, "With the emergence of non-covalent BTK inhibitors, the treatment landscape for CLL or SLL is rapidly evolving. Pirtobrutinib's novel head-to-head evidence against a covalent BTK inhibitor in a BTK inhibitor-naïve population, may offer an important treatment option for both treatment-naïve and relapsed or refractory patients, regardless of prior covalent BTK inhibitor treatment." "This approval marks another significant milestone in the collaboration between Innovent and Lilly, reflecting our shared commitment to bringing innovative therapies to patients with hematologic malignancies in China, said Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent. "As a non-covalent BTK inhibitor, Jaypirca® offers an important treatment option across the full spectrum of CLL/SLL therapy. The approval across lines of therapy further validates the clinical value of pirtobrutinib in CLL/SLL. We will continue to leverage Innovent's professional commercial capabilities in oncology to accelerate patient access to this innovative therapy, to offer Jaypirca® to more Chinese patients with CLL/SLL who may benefit from this treatment." Dr. Li Wang, Lilly Corporate Senior Vice President and Head of Lilly China Drug Development and Medical Affairs Center, said, "The approval of an expanded indication for Jaypirca® in CLL/SLL marks an important milestone for Lilly's ongoing efforts in China to advance innovation for patients with hematologic malignancies. Supported by the robust evidence generated from the BRUIN clinical program, this additional approval for Jaypirca® expands its potential to reach a broader population of patients with CLL/SLL who may benefit. Across all treatment lines, from relapsed or refractory disease to the frontline setting, we hope to help patients achieve better disease management and improve quality of life. Looking ahead, Lilly remains committed to accelerating the introduction of innovative therapies in China and addressing the unmet needs of patients with hematologic cancers." About BRUIN CLL-313 BRUIN CLL-313 is a Phase 3, global, randomized, open-label study of pirtobrutinib versus chemoimmunotherapy (BR) in people with CLL/SLL without 17p deletions who have not been previously treated. The trial enrolled 282 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily) or BR per labeled doses. BR is a chemoimmunotherapy regimen used in the treatment of CLL. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include investigator and IRC-assessed ORR, duration of response (DoR), and PFS, overall survival (OS), time to next treatment (TTNT), safety and tolerability and patient-reported outcomes (PRO). About BRUIN CLL-314 BRUIN CLL-314 is a Phase 3, randomized, open-label noninferiority study of Jaypirca® (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with CLL/SLL who were either treatment-naïve, or who were previously treated and were BTK inhibitor-naïve. The trial enrolled 662 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily) or ibrutinib (420 mg orally, once daily). The primary endpoint is ORR as assessed by blinded IRC. Secondary endpoints include investigator and IRC-assessed PFS, duration of response (DoR) and event-free survival (EFS), and time to next treatment (TTNT), OS, safety and tolerability, and patient-reported outcomes (PRO). About Jaypirca® (Pirtobrutinib) Jaypirca® (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies[3]), non-covalent inhibitor of the enzyme BTK and is the first-and-only approved medicine binding to both wild-type and C481 mutated BTK3. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [4],[5]. In China, pirtobrutinib was developed by Eli Lilly and Company and is commercialized in mainland China by Innovent Biologics. About Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) CLL/SLL is a form of slow-growing non-Hodgkin lymphoma that develops from white blood cells known as lymphocytes[6],[7]. CLL/SLL is one of the most common types of leukemia in adults[8]. There are roughly 100,000 new cases of CLL/SLL globally each year, and the overall incidence of CLL/SLL in China is estimated at approximately 0.39 per 100,000 population[8],[9]. In CLL/SLL, the cancer cells are present in the blood. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage. Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the highquality outbound internationalization of China's innovative drug industry. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza®) and selpercatinib (Retsevmo®), pirtobrutinib (Jaypirca®) and abemaciclib (Verzenios®) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage. Forward-Looking Statements of Innovent Biologics This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. SOURCE Innovent Biologics 21% more press release views with Request a Demo

Clinical ResultPhase 3Drug ApprovalImmunotherapyPhase 2

100 Deals associated with Ramucirumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09371	Ramucirumab	L01FG02	DB05578

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Unresectable Hepatocellular Carcinoma	Japan	Eli Lilly & Co.	20 Jun 2016
Advanced gastric carcinoma	Australia	Eli Lilly Australia Pty Ltd.	23 Jul 2015
Metastatic Gastric Carcinoma	Australia	Eli Lilly Australia Pty Ltd.	23 Jul 2015
Colorectal Cancer	European Union	Eli Lilly Nederland BV	19 Dec 2014
Colorectal Cancer	Iceland	Eli Lilly Nederland BV	19 Dec 2014
Colorectal Cancer	Liechtenstein	Eli Lilly Nederland BV	19 Dec 2014
Colorectal Cancer	Norway	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	European Union	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	Iceland	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	Liechtenstein	Eli Lilly Nederland BV	19 Dec 2014
Hepatocellular Carcinoma	Norway	Eli Lilly Nederland BV	19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction	European Union	Eli Lilly Nederland BV	19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction	Iceland	Eli Lilly Nederland BV	19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction	Liechtenstein	Eli Lilly Nederland BV	19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction	Norway	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	European Union	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	Iceland	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	Liechtenstein	Eli Lilly Nederland BV	19 Dec 2014
Metastatic Colorectal Carcinoma	Norway	Eli Lilly Nederland BV	19 Dec 2014
Non-Small Cell Lung Cancer	European Union	Eli Lilly Nederland BV	19 Dec 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Gastric Adenocarcinoma	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	10 Mar 2021
Non-squamous non-small cell lung cancer	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2021
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2018
Brain metastases	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2018
Hepatitis B	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2018
Pericardial Effusion	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2018
Pleural Effusion	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2018
Superior Vena Cava Syndrome	Phase 3	Japan	Eli Lilly Japan KK	02 Mar 2018
Advanced Hepatocellular Carcinoma	Phase 3	China	Eli Lilly & Co.	13 Jun 2017
Advanced Hepatocellular Carcinoma	Phase 3	China	Lilly Asia Shanghai Representative Office	13 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IKFs602 (ESMO2026)	Phase 3	Metastatic gastroesophageal adenocarcinoma Second line	317	FOLFIRI plus Ramucirumab	cmzglnavzi(gdriviuvfr) = llfhbzvfht zuawhuujgy (luyzumkevb ) View more	Negative	23 Oct 2026
				Paclitaxel plus Ramucirumab	cmzglnavzi(gdriviuvfr) = khkxnpolkm zuawhuujgy (luyzumkevb ) View more
ESMO2026	Not Applicable	Non-Small Cell Lung Cancer CTNNB1 mutations	228	ChT+ICI (EGFR-wt tumors)	pxrufikodq(wjixrzbjey) = zsmbspbubd qhlbhxdfxj (luwakmupsm ) View more	Positive	23 Oct 2026
				iVEGF (bevacizumab/ramucirumab/nintedanib)	pxrufikodq(wjixrzbjey) = lpyuoddols qhlbhxdfxj (luwakmupsm ) View more
NCT05002127 (ASPEN-06, Pubmed \| Nat Med)	Phase 2/3	HER2-positive gastric cancer HER2-positive	127	Evorpacept plus Trastuzumab, Ramucirumab, and Paclitaxel	xtjsfmbsiu(dznuospzii) = seblurnzvs ermipnvpvt (rwzwoexngj ) View more	Positive	24 Sep 2026
				Trastuzumab, Ramucirumab, and Paclitaxel	xtjsfmbsiu(dznuospzii) = paqlfdvvol ermipnvpvt (rwzwoexngj ) View more
NCT04921904 (CTgov)	Phase 1/2	Adenocarcinoma of Esophagus \| Metastatic Gastroesophageal Junction Adenocarcinoma	26	abemaciclib+Ramucirumab	ncbfcoabzn = hmmqzynyfk itzcjhkwkk (uwsmtvpxjx, ltacjsxsaw - dppizckkbz) View more	-	14 Sep 2026
NCT03921671 (RELEVENT, WCLC2026)	Phase 2	thymic carcinoma First line	35	Ramucirumab in combination with carboplatin and paclitaxel	zmemriyiok(prcuqmvjet) = nhodaafuuq gvvebmhdai (ywsvlazncm, 25.1 - 54.3) View more	Positive	12 Sep 2026
NCT03650764 (358, CTgov)	Phase 1/2	Recurrent Squamous Cell Carcinoma of the Head and Neck	43	Pembrolizumab+Ramucirumab (Phase I Dose Level 1 : Ramucirumab (10 mg/kg) + Pembrolizumab)	gtmzithnun = gdmrwwwvdr hidqfkayhg (mgsvsostrd, ggqrvrlrcu - qckgdkzyql) View more	-	17 Aug 2026
				Pembrolizumab+Ramucirumab (Phase II: Ramucirumab (10 mg/kg) + Pembrolizumab)	ubouuoqbea = yaxckehfmg kvrcsnbjoj (xhysjjduyw, vwkrxbceaq - ngymzrlzit) View more
RETRIEVE (ESMO_GI2026)	Phase 2	Advanced Gastric Adenocarcinoma \| Advanced Gastroesophageal Junction Adenocarcinoma Last line	111	FTD/TPI + Ramucirumab	gruesprkmw(muvylednko) = ECOG PS 1 (vs 0) was associated with poorer OS (HR 1.454, 95% CI 1.044–2.027, P = 0.025). qcgtmkvgil (eqrvffbjao ) View more	Positive	02 Jul 2026
				FTD/TPI
NCT04632459 (CTgov)	Phase 2	Metastatic gastric adenocarcinoma \| Metastatic Gastric Carcinoma	26	pembrolizumab+ramucirumab	tfjligkouy = cjutcfkcim aquzskvttb (dcffffteuj, mmlyfqvujf - jyintgwzcx) View more	-	05 Jun 2026
NCT02934464 (ARMANI, ASCO2026)	Phase 3	HER2 negative Gastric Cancer Maintenance HER2-negative	276	Paclitaxel + Ramucirumab	qfmrajaccc(hcpeufpcct) = zrsgvtvfvx lhrxsjavak (xfugjypfxq, 8.5 - 13.5)	Positive	29 May 2026
				Fluoropyrimidine + Oxaliplatin	-
NCT05980000 (ASCO2026)	Phase 2	PD-L1-positive head and neck squamous cell carcinoma First line PD-L1 positive	37	Ramucirumab 10mg/kg and Pembrolizumab 200mg	gnqumivkbr(adctfinwzn) = rgsobldsij zikydbtejr (kqrlkmlqvp, 12.1 - 49.4)	Negative	29 May 2026
				Pembrolizumab	gnqumivkbr(adctfinwzn) = tjgliqctuf zikydbtejr (kqrlkmlqvp, 9.9 - 65.1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis